No immediate trading implications. Monitor upcoming clinical trial updates or financing announcements, which would be more material catalysts for this micro-cap biotech.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 16 $4.14entry
- T+1 · 7mo ago +7.49%α +6.27% · $4.45
- T+5 · 7mo ago +2.66%α +1.67% · $4.25
- T+20 · 6mo ago +0.48%α −5.33% · $4.16
- T+60 · 4mo ago −27.05%α −34.10% · $3.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion held its Annual General Meeting, approving the 2025 Annual Report and re-electing four board members while adding one new director. The filing is a routine corporate governance update with no material financial or strategic developments disclosed.
Key Facts
- Annual General Meeting held on April 16, 2026
- 2025 Annual Report approved
- Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner, and Roberto Prego Pineda re-elected to Board
- Jens Bitsch Nørhave newly elected to Board
- No changes to executive leadership or company strategy announced
Financial Impact
No financial impact
Risk Factors
- Forward-looking statements highlight risks related to funding needs and clinical development
- Small market cap ($35M) increases volatility and sensitivity to future dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275638 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers